Drug with spasmolithic, diuretic and lithiolic action

FIELD: pharmacology.

SUBSTANCE: agent containing belladonna alkaloids, tincture of European madder, magnesium salicylate, a mixture of essential oils with a set of active substances, salicylic acid, linoleic and linolenic acids, ethanol and castor oil is proposed, wherein the substance contains the sum of belladonna alkaloids, recalculated for hyoscyamine as belladonna alkaloids, eucalyptus essential oil, anise essential oil and fennel essential oil as essential oils, and 1,8-cineole eucalyptus essential oil as a biologically active substance with a certain content of the ingredients.

EFFECT: pronounced therapeutic effect in pain elimination and excretion of urinary stones, pronounced anti-inflammatory and diuretic effects.

3 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention represents a composition for surgical area infiltration in liposuction or lymphedema elimination, containing normal saline, 0.5% Naropin and phosphatidylcholine in ratio 9:1:6 respectively per 10-15 cm3 fat.

EFFECT: reducing oedema, tissue injuries and blood loss volume, preventing microcirculation disorders in soft tissues and complications, reducing a risk of recurrences and promoting a faster rehabilitation of the patients.

2 cl

FIELD: chemistry.

SUBSTANCE: invention relates to 4-hydroxy-N-(2-carboxyphenyl)-1-methyl-2,2-dioxo-1H-2λ6 ,1-benzothiazine-3-carboxamide, which possesses diuretic activity.

EFFECT: obtained is novel compound, possessing useful biological activity.

1 tbl, 3 ex

FIELD: biotechnology.

SUBSTANCE: agent is proposed which has diuretic and anti-inflammatory action. It is shown that the sodium salt of 4-carboxyphenyl-O-β-D-glucopyranoside increased the daily diuresis 2 times or more, at that the excretion of sodium and potassium ions is reduced compared to the control; its anti-inflammatory activity is slightly higher than that of nimesulide. Due to the combination of the diuretic effect with anti-inflammatory and antimicrobial activities the agent can be used for the treatment of nephritis, pyelonephritis, cystitis of stagnant phenomena in the systemic and pulmonary circulation due to heart failure.

EFFECT: increased water excretion thus contributing to reduction of swelling.

2 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutics, namely to application of P-methyl-phenyl-O-D-glucopyranoside as medication, which has a diuretic action, which has high diuretic and low saluretic activity.

EFFECT: obtaining medication, which has a diuretic action, which has high diuretic and low saluretic activity.

1 tbl, 1 ex

Diuretic agent // 2500407

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmacology, namely to using "П"-methyl-phenyl-O-D-glucopyranoside as an agent possessing high diuretic and low saluretic activity.

EFFECT: preparing the diuretic drug possessing high diuretic and low saluretic activity.

1 tbl, 1 ex

FIELD: biotechnologies.

SUBSTANCE: peptide of the formula H-(N-Me)-Arg-Lys-Lys-Tyr-Lys-Tyr-Arg-D-Arg-Lys-NH2 is proposed. The proposed peptide may find application as an agent for reduction of pathological hyperpermeability of vessel endothelium in various areas of medicine (in cardiology, toxicology, neurosurgery, oncology, etc.).

EFFECT: prevention of sharp increase of vessel endothelium permeability when injected to a recipient.

3 cl, 4 dwg, 1 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and deals with creation of medication of vegetable origin based on biologically active substances of Linaria vulgaris, which has diuretic and anticoagulation activity. Method of obtaining medication, which has diuretic and anticoagulation activity, consists in the following: extraction of milled grass of Linaria vulgaris with ethyl alcohol is carried out with successive drawing with 3 parts of extractant by method of remaceration with heating and connecting vacuum at the stage of discharge, under specified conditions.

EFFECT: method makes it possible to obtain medication, which has high diuretic and anticoagulation activity.

3 tbl, 1 ex

Diuretic agent // 2487714

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is an agent of diuretic action of a group of aquaretics, phenyl-α-O-D- glucopyranoside. The agent may be used both to treat greater and lesser circulation congestions caused by cardiac failure, and to intensify water release thereby helping to reduce oedemas. The agent has high and low saluretic activity unlike the existing diuretics and expands the range of products of synthetic origin possessing diuretic activity.

EFFECT: agent is applicable for treating the number of cardiovascular diseases accompanied by excessive hydration and developing oedema syndrome.

1 tbl

Diuretic agent // 2484826

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a diuretic of the aquaretic group that is 4-nitro-phenyl-O-D-glucopyranoside. The agent may be used both to treat greater and lesser circulation congestions caused by cardiac failure, and to intensify water release thereby helping to reduce oedemas. The diuretic agent has high and low saluretic activity unlike the existing diuretics and expands the range of products of synthetic origin possessing diuretic activity.

EFFECT: agent is applicable for treating a number of cardiovascular diseases accompanied by excessive hydration and developing oedema syndrome.

1 tbl

FIELD: medicine.

SUBSTANCE: what is described is a new pharmaceutically solid preparation of a vasopressin antagonist which contains: (a) 7-chlor-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro- 1H-benzoazepine and/or its salt; (b) hydroxypropylcellulose containing a hydroxypropoxyl group in the amount of 50% or more; and (c) at least one of the ingredients specified in a group consisting of carmellose, sodium carboxymethyl starch, crospovidone and hydroxypropylcellulose with a lower degree of substitution with an average diameter of particles 30 to 70 mcm and 90% of the cumulative diameter of 100 to 200 mcm.

EFFECT: pharmaceutical solid preparation shows excellent desintegration properties and solubility leading to adequate gastrointestinal absorbability of the active ingredients.

17 cl, 4 tbl, 21 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula

,

possessing properties of binding with delta opioid receptors. In formula I R1 is selected from the group, consisting of phenyl, pyridinyl and thiazolyl, with R1 being optionally substituted with one or two substituents, independently selected from the group, consisting of C1-4alkoxy, fluorine atom, chlorine atom, bromine atom and cyanogroup; in addition, R1 is optionally substituted with di(C1-4alkyl)aminocarbonyl; Y represents O, S, H3, vinyl, ethinyl or S(O); R2 represents a substituent, selected from the group, consisting of hydrogen, C1-4alkyl, C1-4alkoxy, C1-4alkylthio, fluorine atom, chlorine atom, bromine atom and hydroxy; Ra represents hydrogen or methyl; R3 is selected from the group, consisting of pyrrolidin-2-ylmethyl; pyrrolidin-3-ylmethyl; piperidin-2-ylmethyl, piperidin-3-ylmethyl, piperidin-4-ylmethyl, piperidin-2-ylethyl, piperidin-3-ylethyl, piperidin-4-ylethyl, pyridine-4-yl-(C1-2)alkyl, azetidin-3-ylmethyl; morpholin-2-ylmethyl, morpholin-3-ylmethyl, imidazolylmethyl, thiazolylmethyl, (amino)-C3-6cycloalkyl, 3-hydroxy-2-aminopropyl, 8-azabicyclo[3.2.1]octanyl, 1-azabicyclo[2.2.2]octanyl, guanidinylethyl, 4-(imidazol-1-yl)phenylmethyl, 2-(methylamino)ethyl, 2-diethylaminoethyl, 4-diethylaminobut-2-yl, piperidin-3-yl, piperidin-4-yl and pyrrolidin-3-yl; with piperidin-3-yl being optionally substituted on a carbon atom with phenyl; with pyrrolidin-2-yl in pyrrolidin-2-yl-methyl, pyrrolidin-3-yl, piperidin-3-yl and piperidin-4-yl being optionally substituted on a nitrogen atom with methyl, phenylmethyl, phenethyl or methylcarbonyl.

EFFECT: compounds can be used in the treatment of pain, induced by diseases or conditions, such as osteoarthritis, rheumatoid arthritis, migraine, burn, fibromyalgia, cystitis, rhinitis, neuropathic pain, idiopathic neuralgia, toothache, etc.

24 cl, 3 tbl, 19 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to children's urology, and can be intended for conservative treatment of hyperactive urinary bladder in 14-17 year old children. For this purpose introduced is m-anticholinergic "spasmex" in dose 2 mg/year of life, one time per day, in the morning, during 1 month.

EFFECT: method makes it possible to increase efficiency of conservative treatment and reduce daily activity of hyperactive urinary bladder by creation of maximal concentration of medicine in organism.

1 ex

FIELD: otolaryngology.

SUBSTANCE: invention is intended to treat pseudoallergic rhinosinusopathy against a background of parasitic invasion of hepatobiliary system. Elimination of parasites is effected simultaneously with administration of hepatoprotectors and all-purpose membrane stabilizers until clinical is achieved, while cryoconchotomy is performed not later than elimination of parasites is ended.

EFFECT: achieved complete restoration of nasal respiration, reduced incidence of parasitic malady recurrences, and reliably eliminated symptoms of rhinosinusopathy owing to combination of cryoconchotomy and purposive action on hepatobiliary system.

5 cl, 2 ex

FIELD: medicine, urology.

SUBSTANCE: one should affect ureteral area through ureteral projections with flicker-sound magnetic field, its spectral constituents being in the range of the following frequencies 2.5·10-4 - 2.5·101 Hz, and maximal amplitude of magnetic induction - within 0.1-0.5 mcTl. Duration of the procedure corresponds to about 30-60 min. The quantity of procedures - 1-3 daily. At detecting renal stones the diameter being above internal ureteral one should fulfill lithotrypsy before the impact with magnetic field. About 1-2 h before the impact with magnetic field it is necessary to introduce spasmolytic medicinal preparation. In the course of about 30-60 min before the impact with magnetic field and during this impact it is necessary to heat patient's body surface in area of ureteral projection. The innovation enables to shorten the duration of therapy.

EFFECT: higher efficiency.

3 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention proposes the biologically active complex comprising phospholipids and the following biologically active substances - fatty acids, serines, peptides, amino acids, vitamins trace elements and extraction from cattle testicles prepared by successive fractionation with carbon dioxide and ethyl alcohol. The complex provides expanding spectrum of medicinal agents used in dermatological and urological practice and improving quality of the preparation. Invention can be used in treatment of psoriasis, prostatitis caused by prostatitis of sexual disorders.

EFFECT: valuable medicinal properties of complex.

2 tbl

The invention relates to organic chemistry and can find application in medicine

FIELD: medicine.

SUBSTANCE: method involves prescribing a drug therapy comprising administering Tamsulosin, selective alpha-1-adrenoreceptor blocking agent in tablets, orally in a dose of 40 mg with a meal once a day; it is combined with M-cholinomimetic neostigmine methylsulphate injected subcutaneously in 0.05% solution 1 ml that makes a daily dose of 0.5 mg once a day, 6 hours after administering Tamsulosin, selective alpha-1-adrenoreceptor blocking agent. The lithokinetic therapy following the presented schedule is conducted for 1 to 7 days in the period of which calculi are removed from the ureter.

EFFECT: method enables providing more effective calculi removal from the ureter, reducing the length of treatment, reducing the need for surgical manipulations and the number of complications.

2 ex, 1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to phenol derivatives of formula (1), wherein R1 represents C1-C6 alkyl group, C1-C6 alkynyl group, C1-C6 halogen alkyl group, C1-C6 alkyl sulphanyl group or a halogen atom, R2 represents a cyano group or a halogen atom, R3 represents a hydrogen atom, and X represents -S(=O)2. Besides, the invention refers to a drug preparation containing a compound of formula (I) as an active ingredient.

EFFECT: phenol derivatives of formula (1) characterised by the high urine concentration of the permanent compound, and possess the uricosuric action.

11 cl, 1 dwg, 2 tbl, 42 ex

FIELD: chemistry.

SUBSTANCE: claimed invention relates to compounds, represented by formula (I) , where X1 and X2 independently represent CH or N; ring U represents benzene ring, pyrazole ring, 1,2,4-oxadiazole ring, 1,2,4-thiadiazole ring, isothiazole ring, oxazole ring, pyridine ring, thiazole ring or thiophene ring, m represents integer number, which has values from 0 to 1; n represents integer number, which has values from 0 to 3; R1 represents hydroxygroup or C1-6 alkyl; R2 represents any of (1)-(3): (1) halogen atom; (2) hydroxygroup; (3) C1-6 alkyl or C1-6 alkoxy, each of which can independently contain any group, selected from group of substituents α; group of substituents α includes fluorine atom and hydroxygroup, or its pharmaceutically acceptable salt. Invention also relates to pharmaceutical composition, possessing inhibiting activity with respect to xanthenes oxidase, including formula (I) compound or its pharmaceutically acceptable salt as active ingredient.

EFFECT: derivative, which contains condensed ring structure, intended as means for prevention and treatment of disease, associated with abnormal level of uric acid in serum.

15 cl, 11 tbl, 126 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely saxifragant herbal tea. The saxifragant herbal tea contains meadowsweet root, sunflower root, sloe root, wild rose root, as well as agrimony and wild carrot seeds; all roots are milled, all the ingredients are taken in equal proportions.

EFFECT: herbal tea has the improved saxifragant and calculus-excretion properties.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely rehabilitation medicine, physiotherapy and urology and may be used for the purpose of rehabilitation of the patients suffering urolithiasis following lithitripsy. That is ensured by the intake of the herbal tea "Veres" containing wild camomile blossom, knotgrass herb, nosebleed herb and horsetail herb, juniper fruits, sage leaves, birch leaves, red bilberry leaves, linseeds taken in equal proportions. The infusion is taken in a dose of 100 ml 3 times a day 30 minutes before meals for 5-7 preoperative days. The common background therapy follows the lithotripsy procedure. That is combined with the additional intake of the herbal tea "Veres" for 10 days following the above procedure and hydrocarbonate sulphate calcium-magnesium mineral water "Kazachinskaya" of mineralisation 1.44g/l for 24 days following lithotripsy. The mineral water "Kazachinskaya" is taken in a dose of 200-250 ml 3 times a day before meals. Further, after the lithotripsy procedure, a projection of the involved kidneys and renal duct is exposed to the apparatus Bemer-3000 at AC field frequency 30-1000 Hz and magnetic field intensity 8.5-100 mcT. The exposure is generated by an intensive contact applicator from 2 fields in the mode-1 (2-4 stages) of 8 minutes. The therapeutic course makes 10 daily procedures. The background therapy is followed by another one-month intake of the herbal tea "Veres", as well as by another exposure to the apparatus "Bemer-3000" at the same parameters of the electromagnetic field. The contact exposure also covers the kidneys and the lower one-third of the renal duct by means of the intensive application from 2-4 fields in the mode-2 (2-4 stages) of 12 minutes. The exposure is daily, two times a day.

EFFECT: method provides reducing the length of calculus fragments discharge following the lithotripsy procedure, improving the clinical and biochemical blood and urine statuses, renal blood flow, treating and preventing the postoperative complications, recovering the immunological responsiveness and antioxidant protection.

4 dwg, 3 tbl, 2 ex

Up!